These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28 related articles for article (PubMed ID: 12602372)
1. [Verteporfin and photosensitivity in diabetic]. Asensio Sánchez VM; Corral Azor A; García Pascual A Arch Soc Esp Oftalmol; 2003 May; 78(5):277-9. PubMed ID: 12789632 [TBL] [Abstract][Full Text] [Related]
2. [Dynamic phototherapy with silicone oil in treating choroidal subfoveal neovascularization in high myopia]. Soler V; Pagot-Mathis V; Quintyn JC J Fr Ophtalmol; 2011 Oct; 34(8):561.e1-4. PubMed ID: 21570149 [TBL] [Abstract][Full Text] [Related]
3. [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014]. Pauleikhoff D; Bertram B; Claessens D Ophthalmologe; 2014 Mar; 111(3):229-34. PubMed ID: 24633460 [No Abstract] [Full Text] [Related]
8. Verteporfin: new indication. In certain age-related macular degeneration: too little evidence. Prescrire Int; 2004 Feb; 13(69):7-9. PubMed ID: 15055207 [TBL] [Abstract][Full Text] [Related]
9. Verteporfin: new preparation. In combination with laser therapy: helpful in some forms of age-related macular degeneration. Prescrire Int; 2001 Jun; 10(53):78-81. PubMed ID: 11718169 [TBL] [Abstract][Full Text] [Related]
10. Verteporfin in Photodynamic Therapy: report no. 5. Bandello F; Blinder K; Bressler NM; Brown AL; Miller JW; Potter MJ; Pournaras C; Reaves A; Rosenfeld PJ; Slakter JS; Soubrane G; Strong HA; Stur M; Ophthalmology; 2004 Nov; 111(11):2144. PubMed ID: 15522385 [No Abstract] [Full Text] [Related]
13. Verteporfin: new indication. New indication in complications of high myopia: no sustained benefit. Prescrire Int; 2003 Feb; 12(63):5-8. PubMed ID: 12602372 [TBL] [Abstract][Full Text] [Related]